Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $895
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an 'Overweight' rating on Regeneron Pharmaceuticals and raised the price target from $885 to $895.
November 03, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals' price target has been raised by Piper Sandler from $885 to $895, maintaining an 'Overweight' rating.
The raised price target and 'Overweight' rating by Piper Sandler indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100